Pharmaceutical commercialization is getting more challenging every day. Analytics talent is in high demand to support informed and insightful business decisions across a global landscape. Yet, despite the increasing market complexity, most commercialization leaders are facing cost reduction pressure resulting in the exploration and assignment of work to lower-cost alternatives.
In terms of analytics support, there are typically two resource plans to choose from: Plan A: Continue the analytics function with onshore support for a high quality solution Plan B: Replace the analytics function fully or partially with offshore support for cost savings
Does either plan provide a viable solution for commercialization leaders to have efficient and cost-effective analytics support? What challenges will one run into by choosing either plan? Let’s take a closer look at what has happened in analytics groups